Expression of CLDN18.2 in Invasive Mucinous Adenocarcinomas of the Lung.

Kunio Mochizuki; Ippei Tahara; TOMOHIRO INOUE; Kazunari Kasai; Tetsuo Kondo

doi:10.21873/cdp.10521

March 4, 2026Open Access

Expression of CLDN18.2 in Invasive Mucinous Adenocarcinomas of the Lung.

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to investigate the expression of CLDN18.2 in invasive mucinous adenocarcinomas of the lung compared to other subtypes.
Examined CLDN18.2 expression in lung adenocarcinomas.
Compared expression levels between invasive mucinous adenocarcinomas and other major lung cancer subtypes.
CLDN18.2 is frequently expressed in invasive mucinous adenocarcinomas.
Rare expression of CLDN18.2 in other major lung cancer subtypes was observed.
Zolbetuximab may be a promising targeted therapy for these specific cancers.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This research shows that CLDN18.2 is frequently expressed in invasive mucinous adenocarcinomas, suggesting zolbetuximab may be a targeted treatment.

Abstract

CLDN18.2 is frequently expressed in IMAs but rarely in other major lung cancer subtypes, suggesting that zolbetuximab may represent a promising targeted therapy for IMA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mochizuki et al. (2026) studied this question.

synapsesocial.com/papers/69aa6ee2531e4c4a9ff5906c https://doi.org/10.21873/cdp.10521

View Full Paper

Ask AI

Bookmark

Share

Expression of CLDN18.2 in Invasive Mucinous Adenocarcinomas of the Lung.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Expression of CLDN18.2 in Invasive Mucinous Adenocarcinomas of the Lung.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading